Drug
Patiromer
Patiromer: highest development phase Post-Market, developed by Vifor Pharma. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Vifor Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| patiromer NCT02694744 | Post-Market | Hyperkalemia |
| Patiromer NCT03888066 | Phase 3 | Hyperkalemia |
| Patiromer NCT01810939 | Phase 3 | Chronic Kidney Disease (CKD) |
| patiromer NCT01130597 | Phase 2 | Heart Failure |
| patiromer NCT01371747 | Phase 2 | Chronic Kidney Disease |
| patiromer NCT02033317 | Phase 2 | Hyperkalemia |
| Patiromer NCT05766839 | Phase 2 | Hyperkalemia |
| Patiromer NCT03087058 | Phase 2 | Hyperkalemia |
Latest
No recent events.
Follow Patiromer on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.